John Ramsey
Psychiatric/Mental Health · Omaha, NENPI 1013558287
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Johnson & Johnson$795
- Otsuka America Pharmaceutical, Inc.$772
- Alkermes, Inc.$472
- Gilead$445
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $1,568 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 53 | $1,138 |
| Johnson & Johnson | 26 | $795 |
| Otsuka America Pharmaceutical, Inc. | 31 | $772 |
| Alkermes, Inc. | 26 | $472 |
| Gilead | 4 | $445 |
| Supernus Pharmaceuticals, Inc. | 19 | $302 |
| Lundbeck LLC | 15 | $265 |
| Axsome Therapeutics, Inc. | 10 | $259 |
| E.r. Squibb & Sons, L.L.C. | 6 | $223 |
| Ironshore Pharmaceuticals Inc. | 9 | $223 |
| Tris Pharma Inc | 10 | $205 |
| Teva Pharmaceuticals USA, Inc. | 10 | $195 |
| Corium, LLC | 15 | $191 |
| Viiv Healthcare Company | 4 | $187 |
| Vanda Pharmaceuticals Inc. | 6 | $155 |
| Noven Therapeutics, LLC | 3 | $154 |
| Harmony Biosciences LLC | 2 | $143 |
| Sunovion Pharmaceuticals Inc. | 6 | $119 |
| Neos Therapeutics, LP | 8 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $92 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Almatica Pharma LLC | 3 | $55 |
| Merck | 2 | $26 |
| Lilly USA, LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$846
- VRAYLAR$695
- INVEGA SUSTENNA$258
- CAPLYTA$250
- ABILIFY MAINTENA$250
- QELBREE$199
- INVEGA TRINZA$148
- Biktarvy$146
- REXULTI$125
- Wakix$125
- SPRAVATO$125
- COBENFY$122
- JORNAY PM$122
- Xelstrym$121
- APRETUDE$120
- Auvelity$120
- ABILIFY ASIMTUFII$120
- Yeztugo$107
How this compares
$8,203 in reported general payments places this provider in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 15 | $23,291 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 11 | $1,222 |
| Bupropion XlBupropion Hcl | 21 | $827 |
| Aripiprazole | 37 | $813 |
| Lorazepam | 38 | $464 |
| Gabapentin | 16 | $453 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $397 |
| Benztropine Mesylate | 17 | $342 |
| Olanzapine | 11 | $334 |
| Quetiapine Fumarate | 11 | $307 |
| Doxepin Hcl | 12 | $301 |
| Prazosin Hcl | 12 | $276 |
| Mirtazapine | 11 | $264 |
| Alprazolam | 22 | $215 |
| Duloxetine Hcl | 11 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,568 | $23,29115 claims |
| Lilly USA, LLCOlanzapine | $18 | $33411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Omaha
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Julie ZulkoskyOmaha$8K
- M Joyce SasseOmaha$7K
- Molly PetersenOmaha$6K
- Salina AndersonOmaha$6K
- Heather WilhelmOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.